ATE297207T1 - 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten - Google Patents
4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonistenInfo
- Publication number
- ATE297207T1 ATE297207T1 AT99931887T AT99931887T ATE297207T1 AT E297207 T1 ATE297207 T1 AT E297207T1 AT 99931887 T AT99931887 T AT 99931887T AT 99931887 T AT99931887 T AT 99931887T AT E297207 T1 ATE297207 T1 AT E297207T1
- Authority
- AT
- Austria
- Prior art keywords
- subtype
- piperidine
- benzyl
- receptor antagonists
- nmda receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9091498P | 1998-06-26 | 1998-06-26 | |
PCT/US1999/014291 WO2000000197A1 (en) | 1998-06-26 | 1999-06-25 | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE297207T1 true ATE297207T1 (de) | 2005-06-15 |
Family
ID=22224939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99931887T ATE297207T1 (de) | 1998-06-26 | 1999-06-25 | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten |
Country Status (28)
Country | Link |
---|---|
US (1) | US6284774B1 (de) |
EP (1) | EP1089735B1 (de) |
JP (1) | JP2002519322A (de) |
KR (1) | KR20010053170A (de) |
CN (1) | CN1304307A (de) |
AP (1) | AP2000001949A0 (de) |
AT (1) | ATE297207T1 (de) |
AU (1) | AU769650B2 (de) |
BG (1) | BG105082A (de) |
BR (1) | BR9911575A (de) |
CA (1) | CA2327888A1 (de) |
DE (1) | DE69925730T2 (de) |
EA (1) | EA200100058A1 (de) |
EE (1) | EE200000778A (de) |
ES (1) | ES2244201T3 (de) |
HU (1) | HUP0102471A2 (de) |
ID (1) | ID28005A (de) |
IL (1) | IL138949A0 (de) |
IS (1) | IS5667A (de) |
NO (1) | NO20006482L (de) |
NZ (1) | NZ508808A (de) |
OA (1) | OA11570A (de) |
PE (1) | PE20000728A1 (de) |
PL (1) | PL345024A1 (de) |
SK (1) | SK19512000A3 (de) |
TR (1) | TR200003888T2 (de) |
WO (1) | WO2000000197A1 (de) |
ZA (1) | ZA200005848B (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
BR0110247A (pt) * | 2000-04-26 | 2003-03-05 | Warner Lambert Co | Derivado de ciclohexilamina como antagonistas de receptor de nmda seletivos em subtipo |
JP2003535073A (ja) | 2000-06-01 | 2003-11-25 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | サブタイプ選択性nmdaレセプター拮抗物質としてのシクロヘキシルアミン誘導体 |
ES2291329T3 (es) * | 2000-07-18 | 2008-03-01 | Dainippon Sumitomo Pharma Co., Ltd. | Inhibidores de la recaptacion de serotonina. |
IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
HUP0303258A3 (en) | 2001-02-23 | 2004-06-28 | Merck & Co Inc | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them |
WO2002072542A2 (en) * | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
CA2381630A1 (en) * | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
RS50767B (sr) | 2001-07-24 | 2010-08-31 | Richter Gedeon Vegyeszeti Gyar Rt. | Piperidinski derivati kao antagonisti nmda receptora |
ES2429132T3 (es) | 2001-08-31 | 2013-11-13 | The Rockefeller University | Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro |
US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
RU2004121177A (ru) * | 2001-12-11 | 2005-03-10 | Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us) | Применение прамипексола для лечения бокового амитрофического склероза |
US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
EP1845968A2 (de) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen |
EP2425846A1 (de) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit |
DE602006009670D1 (de) * | 2005-08-15 | 2009-11-19 | Univ Virginia | Neurorestauration mit r(+) pramipexol |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
CN101448498B (zh) | 2006-05-16 | 2011-04-27 | 诺普神经科学股份有限公司 | R(+)和s(-)普拉克索的组合物以及使用该组合物的方法 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP2142514B1 (de) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
KR20100045983A (ko) * | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 nmda 수용체 길항물질 |
DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
TWI410420B (zh) * | 2008-02-05 | 2013-10-01 | Dainippon Sumitomo Pharma Co | 苄基哌啶化合物 |
CA2721360A1 (en) * | 2008-04-18 | 2009-10-22 | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting F Or And On Behalf Of The University Of Arizona | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration |
CN102186350A (zh) | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
HUP0900130A3 (en) | 2009-03-03 | 2012-02-28 | Richter Gedeon Nyrt | Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation |
JPWO2011016468A1 (ja) | 2009-08-04 | 2013-01-10 | 大日本住友製薬株式会社 | ベンジルピペリジン化合物 |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
MX2012006320A (es) | 2009-12-02 | 2013-01-18 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤 |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
BR112014012167A2 (pt) | 2011-11-22 | 2017-05-30 | The Regents Of The Univ Of Calefornia | métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
EP3838271A1 (de) | 2013-07-12 | 2021-06-23 | Knopp Biosciences LLC | Behandlung eines erhöhten spiegels von eosinophilen und/oder basophilen |
CA2921378A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
DK3033081T3 (da) | 2013-08-13 | 2021-05-31 | Knopp Biosciences Llc | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria |
US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
EP3233077A4 (de) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamin-d2-rezeptor-liganden |
MX2020002078A (es) | 2017-08-24 | 2020-09-21 | Adamas Pharma Llc | Composiciones de amantadina, preparaciones de estas y métodos de uso. |
EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
WO2020219975A1 (en) * | 2019-04-26 | 2020-10-29 | Cytosolve, Inc. | Compositions for improving brain health and memory |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792187A (fr) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | Nouveaux derives d'alkylamines |
DE2845537A1 (de) | 1978-10-19 | 1980-04-30 | Bayer Ag | Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
JPH05194505A (ja) * | 1991-08-09 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | チオフェン化合物 |
US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
JP2959615B2 (ja) * | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
ES2128629T3 (es) | 1994-10-31 | 1999-05-16 | Merck Patent Gmbh | Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos. |
CA2217200A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel method |
ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
WO1998015550A1 (en) * | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
-
1999
- 1999-06-24 PE PE1999000567A patent/PE20000728A1/es not_active Application Discontinuation
- 1999-06-25 ID IDW20002514A patent/ID28005A/id unknown
- 1999-06-25 KR KR1020007014745A patent/KR20010053170A/ko not_active Application Discontinuation
- 1999-06-25 EE EEP200000778A patent/EE200000778A/xx unknown
- 1999-06-25 IL IL13894999A patent/IL138949A0/xx unknown
- 1999-06-25 TR TR2000/03888T patent/TR200003888T2/xx unknown
- 1999-06-25 DE DE69925730T patent/DE69925730T2/de not_active Expired - Fee Related
- 1999-06-25 WO PCT/US1999/014291 patent/WO2000000197A1/en active IP Right Grant
- 1999-06-25 PL PL99345024A patent/PL345024A1/xx unknown
- 1999-06-25 HU HU0102471A patent/HUP0102471A2/hu unknown
- 1999-06-25 NZ NZ508808A patent/NZ508808A/xx unknown
- 1999-06-25 EA EA200100058A patent/EA200100058A1/ru unknown
- 1999-06-25 OA OA1200000347A patent/OA11570A/en unknown
- 1999-06-25 SK SK1951-2000A patent/SK19512000A3/sk unknown
- 1999-06-25 AT AT99931887T patent/ATE297207T1/de not_active IP Right Cessation
- 1999-06-25 ES ES99931887T patent/ES2244201T3/es not_active Expired - Lifetime
- 1999-06-25 CN CN99807087A patent/CN1304307A/zh active Pending
- 1999-06-25 US US09/674,298 patent/US6284774B1/en not_active Expired - Fee Related
- 1999-06-25 AP APAP/P/2000/001949A patent/AP2000001949A0/en unknown
- 1999-06-25 CA CA002327888A patent/CA2327888A1/en not_active Abandoned
- 1999-06-25 JP JP2000556782A patent/JP2002519322A/ja active Pending
- 1999-06-25 AU AU48303/99A patent/AU769650B2/en not_active Ceased
- 1999-06-25 BR BR9911575-1A patent/BR9911575A/pt not_active Application Discontinuation
- 1999-06-25 EP EP99931887A patent/EP1089735B1/de not_active Expired - Lifetime
-
2000
- 2000-10-16 IS IS5667A patent/IS5667A/is unknown
- 2000-10-19 ZA ZA200005848A patent/ZA200005848B/en unknown
- 2000-12-19 NO NO20006482A patent/NO20006482L/no not_active Application Discontinuation
- 2000-12-21 BG BG105082A patent/BG105082A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002519322A (ja) | 2002-07-02 |
WO2000000197A1 (en) | 2000-01-06 |
EP1089735B1 (de) | 2005-06-08 |
NZ508808A (en) | 2002-12-20 |
BR9911575A (pt) | 2001-03-20 |
ZA200005848B (en) | 2001-12-18 |
EE200000778A (et) | 2002-04-15 |
DE69925730T2 (de) | 2006-03-23 |
DE69925730D1 (de) | 2005-07-14 |
HUP0102471A2 (hu) | 2002-05-29 |
CN1304307A (zh) | 2001-07-18 |
AU4830399A (en) | 2000-01-17 |
SK19512000A3 (sk) | 2001-08-06 |
ES2244201T3 (es) | 2005-12-01 |
IS5667A (is) | 2000-10-16 |
KR20010053170A (ko) | 2001-06-25 |
EP1089735A1 (de) | 2001-04-11 |
US6284774B1 (en) | 2001-09-04 |
EP1089735A4 (de) | 2002-12-18 |
CA2327888A1 (en) | 2000-01-06 |
AP2000001949A0 (en) | 2000-12-31 |
NO20006482D0 (no) | 2000-12-19 |
AU769650B2 (en) | 2004-01-29 |
IL138949A0 (en) | 2001-11-25 |
PL345024A1 (en) | 2001-11-19 |
PE20000728A1 (es) | 2000-08-21 |
BG105082A (en) | 2001-09-28 |
ID28005A (id) | 2001-05-03 |
NO20006482L (no) | 2000-12-19 |
TR200003888T2 (tr) | 2001-06-21 |
OA11570A (en) | 2004-07-01 |
EA200100058A1 (ru) | 2001-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE297207T1 (de) | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
DE60015296D1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
DE69921124D1 (de) | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden | |
ATE261945T1 (de) | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten | |
ATE250039T1 (de) | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten | |
DK1009732T3 (da) | 1-Amino-alkylcyclohexan NMDA receptor antagonister | |
DE69812096D1 (de) | Neuropeptid y rezeptorantagonisten | |
DE69509765D1 (de) | N-heterocyclyl sulphonamid-derivate und ihre verwendung als endothelin-antagonisten | |
ATE496032T1 (de) | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten | |
DE69531458D1 (de) | Chinolinderivate als tachykinin nk3 rezeptor antagonisten | |
ID19623A (id) | Antagonis reseptor vitronektin | |
DE69728392D1 (de) | Indolderivate verwendbar als endothelinrezeptorantagonisten | |
ATE280157T1 (de) | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii | |
DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
DE59914921D1 (de) | 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4-benzylpiperidine als nmda-rezeptor-antagonisten | |
ATE272632T1 (de) | Muskarin-rezeptor antagonisten | |
ID24726A (id) | Antagonis-antagonis reseptor trombin | |
ID26223A (id) | Antagonis reseptor vitronektin | |
ID24162A (id) | Antagonis-antagonis reseptor vitronektin | |
ATE353881T1 (de) | 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten | |
ID28811A (id) | Antagonis reseptor vitronektin | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
ATE196766T1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten | |
DE69408674D1 (de) | Phenylpyrrol-derivate und ihre verwendung als dopamin d3 antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |